ARCH Arch Biopartners Inc.

TSXV · CA · Healthcare · Biotechnology · archbiopartners.com

0.8300CAD0.00%Mkt Cap: 41.06M $P/E: —3d ago

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which i…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap41.06M USD

Enterprise Value43.05M USD

Revenue (TTM)0 USD

Gross Profit-541.70K USD

Net Income (TTM)-1.13M USD

Revenue/Share0.00 CAD

Last Price0.8300 CAD

Fiscal Year EndSep 2025

MR QuarterJun 2026

Employees—

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/SInfinity

P/B-14.07

EPS (TTM)-0.05

EPS (Forward)—

52W Range

0.390035% of range1.660

52W High1.660 CAD

52W Low0.3900 CAD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE40.00%

ROA-1485.45%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-1.25M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-1.33%

Net Debt1.98M USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity-0.64

Current Ratio0.01

Quick Ratio0.01

Book Value/Sh-0.06 CAD

Cash/Share0.00 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div DateSep 13, 2000

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.67.93M

Float53.61M

Insiders18.18%

Institutions0.00%

Short Interest

Short Ratio0.0d

Short % Out.0.00%

Shares Short858

Short (prev mo.)40.55K

Technical

SMA 500.9600 (-13.5%)

SMA 2000.8241 (+0.7%)

Beta1.75

S&P 52W Chg14.58%

Avg Vol (30d)60.61K

Avg Vol (10d)48.31K

Technical Indicators

RSI (14)42.4

MACD-0.0294

MACD Signal-0.0236

MACD Hist.-0.0058

BB Upper1.036 CAD

BB Middle0.8950 CAD

BB Lower0.7542 CAD

BB Width31.45%

ATR (14)0.0873 CAD

Vol Ratio (20d)0.07x